Azitra (AZTR) Gains from Investment Securities (2022 - 2026)
Azitra (AZTR) reported Gains from Investment Securities of $4261.0 for Q1 2026, up 3079.72% on a YoY basis from $134.01 in Q1 2025, and up 152.43% quarter-over-quarter from $1688.0 in Q4 2025.
Azitra (AZTR) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Azitra has reported Gains from Investment Securities for 5 years, with the latest figure at $4261.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 3079.72% year-over-year to $4261.0; the trailing twelve-month figure through Mar 2026 stood at $2705.0 (up 100.07% YoY), and the FY2025 full-year result was -$381.0, up 99.99% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $4261.0, up from $1688.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $2.0 million in Q1 2023, with the low at -$4.0 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged $39775.0 across 5 years, with a median of $1688.0 in 2025.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities tumbled 9127.98% — and 2026, when it jumped 3079.72%.
- Azitra's Gains from Investment Securities stood at $7102.0 in 2022, then plunged by 714.8% to -$43663.0 in 2023, then plunged by 9127.98% to -$4.0 million in 2024, then surged by 100.04% to $1688.0 in 2025, then jumped by 152.43% to $4261.0 in 2026.
- The last three Gains from Investment Securities figures came in at $4261.0 (Q1 2026), $1688.0 (Q4 2025), and -$3244.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,261.00 |
| Mar 31, 2026 | 4,261.00 |
| Dec 31, 2025 | 1,688.00 |
| Dec 31, 2025 | 1,688.00 |
| Sep 30, 2025 | -3,244.00 |
| Sep 30, 2025 | -3,244.00 |
| Mar 31, 2025 | -143.00 |
| Mar 31, 2025 | -143.00 |
| Dec 31, 2024 | -4.03 Mn |
| Dec 31, 2024 | -4.03 Mn |
| Sep 30, 2024 | -4,859.00 |
| Sep 30, 2024 | -4,859.00 |
| Dec 31, 2023 | -43,663.00 |
| Dec 31, 2023 | -43,663.00 |
| Sep 30, 2023 | 42,070.00 |
| Sep 30, 2023 | 42,070.00 |
| Jun 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.26 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.00 Mn |